Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Raute Corporation - Managers' transactions - Mika Mustakallio

RAUTE CORPORATION MANAGERS' TRANSACTIONS 14 NOVEMBER 2017 at 10:30 a.m.Raute Corporation - Managers' transactions - Mika Mustakallio____________________________________________ Person subject to the notification requirementName: Mika MustakallioPosition: Member of the Board(X) Legal personIssuer: Raute CorporationLEI: 743700G00629V99PE435 Notification type: INITIAL NOTIFICATIONReference number: 743700G00629V99PE435_20171114082235_4____________________________________________ Transaction date: 2017-11-09Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHARE

Raute Corporation - Managers' transactions - Tapani Kiiski

RAUTE CORPORATION MANAGERS' TRANSACTIONS 14 NOVEMBER 2017 at 10:25 a.m.Raute Corporation - Managers' transactions - Tapani Kiiski____________________________________________ Person subject to the notification requirementName: Kiiski, TapaniPosition: Chief Executive OfficerIssuer: Raute CorporationLEI: 743700G00629V99PE435 Notification type: INITIAL NOTIFICATIONReference number: 743700G00629V99PE435_20171113185902_2____________________________________________ Transaction date: 2017-11-13Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009004741

Episealer® 24 months’ clinical study results accepted for publication in peer-reviewed scientific journal

Episurf Medical (NASDAQ: EPIS B) today announces that a peer-reviewed article with clinical data on 10 Episealer® knee implant patients with 24 months’ follow-up now is accepted for publication. The publication with the title “A customized femoral resurfacing metal implant for focal chondral lesions - radiostereometric analysis and subjective outcome of the first ten patients” by Stålman, A., Sköldenberg, O., Martinez-Carranza, N., Högström, M. and Ryd, L. will be published in the journal Knee Surgery, Sports Traumatology, Arthroscopy and is shortly available online. The study behind

Bayn awards the best research in sugar reduction or sugar alternatives At the sugar reduction award 2017, London

The inaugural Sugar Reduction Awards took place alongside The Sugar Reduction Summit at The Royal Society London, on Thursday 9thNovember. The Awards were launched to recognise and celebrate the progress that has been made in sugar reduction across public health, education, academia, manufacturing and supply chains, and were supported by Layn, Sugarwise and Bayn Europe.  The Awards were judged by a carefully selected and balanced panel of 14 industry and academic experts including Judy Buttriss from the British Nutrition Foundation, Sara Petersson from Euromonitor, Prof Jason Halford

Kindred Group expands into top modern premises in Stockholm

The gambling operator Kindred Group secures further expansion in Stockholm by signing a lease agreement with AMF Fastigheter in their new project Urban Escape in central Stockholm. The move into new premises is part of the company’s expressed ambition to be a leading tech company in Stockholm.Kindred Group (previously Unibet Group) has signed a lease agreement with AMF Fastigheter in the first-class city development project Urban Escape on Regeringsgatan 27 in central Stockholm. Kindred, one of Europé’s leading online gambling operators with brands such as Unibet, MariaCasino, iGame,

UPM Raflatac expands Lite range of ecodesigned labeling solutions with new PP Clear FTC Lite film

(UPM Raflatac, Helsinki, 14 November 2017 at 10:00 EET) - UPM Raflatac has expanded its PP Lite range of labeling solutions for the European market with the introduction of a new clear film, PP Clear FTC Lite. The face materials, adhesives, and backing used in the PP Lite range offer brands new ways to achieve their sustainability objectives. PP Lite label materials offer brand owners the opportunity to differentiate themselves from the competition by becoming a leader in sustainable product labeling while boosting productivity across the value chain at the same time. By combining a

Sectra wins deal as Dutch hospitals merge and consolidate imaging

Linköping, Sweden – November 14, 2017 –  International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) has signed a PACS contract with the Dutch hospital Zuyderland. Zuyderland is a merger of two hospitals that have now chosen to replace their separate IT environments for reviewing radiology and nuclear medicine images and consolidate in a single common system from Sectra. The enterprise-wide solution will give physicians at Zuyderland a consolidated patient overview regardless of which hospital a patient has previously visited.“When merging, we of

Patent cases dismissed

In October 2013, Accumulate AB filed a lawsuit against Seamless Distribution AB (publ) for alleged patent infringement. In August 2014, Seamless filed a lawsuit against Accumulate where Seamless claimed that Accumulate’s patent should be declared invalid. On September 15, 2017, the Swedish Patent and Market Court announced its judgements in both cases. The judgements were appealed by Accumulate to the Swedish Patent and Market Court of Appeal, and the court has now decided to dismiss both cases. The reason behind the dismissal of the cases is that the parties have reached a settlement

DIGNITANA MOVING OPERATIONS TO THE U.S.

Lund, 14 November, 2017 - Dignitana AB, a world leader in medical scalp cooling technology and manufacturer of The DigniCap® Scalp Cooling System, today announced efficiency measures for its Swedish operations. Today, Dignitana AB's operations in Lund are focused on product development, production, quality and finance, while Dignitana Inc. in the U.S. handles sales, marketing and customer support. Dignitana AB intends to relocate operations from its head office in Lund, to the company's subsidiary in the U.S. As a result, all Dignitana AB functions will be transferred to Dignitana Inc.

Karessa Pharma Holding AB announces today that the first patient is dosed in the company's clinical study with K-03 Vardenafil buccal film

Today, the dosing of healthy volunteers begins in Karessa's clinical trial K-03/1 buccal film. The study will last for five weeks and is planned to be completed on 15th of December 2017.The study is a Phase I, open, randomized, single-center study on healthy male subjects in order to determine the PK profile in the body (pharmacokinetic profile) of Vardenafil given as K-03/1 buccal film. The study consists of comparing the PK profile of four different variants of K-03/1 buccal film. Except for the evaluating of PK profile, the safety and tolerability of Karessa's K-03/1 buccal film will

Stillfront Group AB: Stillfront Interim Report January-September 2017

Interim Report January-September 2017 Press Release November 14, 2017   STILLFRONT GROUP AB (PUBL) The interim period January - September 2017 · Net revenues amounted to 112.7 MSEK (corresponding period 2016: 70.3 MSEK), which is an increase of 60% compared to the corresponding period 2016. Total operating revenues amounted to 139.2 MSEK (87.0). · EBITDA amounted to 36.9 MSEK compared to 27.5 during the corresponding period 2016. EBITDA has increased due to a written-off debt and has been charged with acquisition costs, costs pertaining to improved IT infrastructure at

OmniCar holding AB announces new board member

We are very pleased to announce that Andreas Klainguti has accepted to join the board of directors of OmniCar Holding AB. Andreas Klainguti will be replacing Mikkel Lippmann, COO at Omnicar Holding AB.Andreas Klainguti has worked for more than 25 years in Investment Banking for Merrill Lynch, Standard Chartered Bank and Citigroup in Zurich, London and Hong Kong. As a Manging Director he was Head of Derivatives EMEA and Asia, Head of Global Equity Trading and Head of Global Strategic Risk. Since moving to Denmark in 2013 he has been advising various Banks and Hedge Funds on Business set up,

Etrion Releases Third Quarter 2017 Results

November 14, 2017, Miami, Florida, United States – Etrion Corporation (“Etrion” or the “Company”) (TSX: ETX) (OMX: ETX), a solar independent power producer, today released its condensed consolidated interim financial statements and related management’s discussion and analysis (“MD&A”) for the three and nine months ended September 30, 2017.  Etrion Corporation delivered strong project-level results in the third quarter of 2017 driven by the Japanese assets. Higher installed capacity and electricity production resulted in a significant increase in revenue and project-level EBITDA compared

Odfjell SE signs Framework Agreement with Sinochem Shipping Singapore Pte. Ltd to take 4 stainless steel vessels on long-term bareboat charters and to form a pool of 8 chemical tankers

Odfjell SE ("Odfjell") has signed a Framework Agreement with Sinochem Shipping Singapore Pte. Ltd ("Sinochem") whereby Odfjell will take 4 of a total newbuilding order of 8 x 40,900 dwt chemical tankers on long-term bareboat charters. The bareboat charters include purchase options at the end of the charter period. Sinochem will continue to own 4 vessels, which together with the 4 bareboat vessels will form a pool of 8 x 40,900 dwt sophisticated chemical tankers. The pool will be managed by Odfjell SE and the vessels will trade as part of the Odfjell Tankers fleet. The series of

New Swedish study results at SABCS show DiviTum® blood test reduces waiting times for evaluating breast cancer treatment

Uppsala, Sweden, November 14, 2017. Results from a study of 142 women with newly diagnosed metastatic breast cancer will be presented by researchers from Lund University at the world’s biggest breast cancer conference in San Antonio, USA. The study demonstrates that the DiviTum® blood-based biomarker can provide more accurate prognosis than today’s standard methods.With imaging methods used for evaluating the effect of treatment, it takes about three months to evaluate whether the given therapy is effective or not. The new study demonstrates that DiviTum® accurately can predict outcome (

BONESUPPORT™ - CERAMENT® G’s POTENTIAL TO PREVENT AND MANAGE BIOFILM-RELATED BONE INFECTIONS HIGHLIGHTED IN NEW HIGH-PROFILE PUBLICATION

Lund, Sweden, 08.00 CET, 14 November 2017 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform announces the publication of a paper highlighting the anti-biofilm activity of CERAMENT® G in vitro - Colloids and Surfaces B: Biointerfaces 161 (2018) 252–260. Implant-related bone infections caused by microorganisms that grow in biofilms are extremely difficult to treat and cause persistent and recurring infections. The use of

BerGenBio Presents BGB324 and KEYTRUDA® (pembrolizumab) Clinical Trial at the 2017 San Antonio Breast Cancer Symposium

Bergen, Norway, 14 Nov 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, is pleased to announce that the Company will present its recently initiated Phase II clinical trial investigating BGB324 in combination with the Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with triple negative breast cancer (TNBC) at the 2017 San Antonio Breast Cancer Symposium in San Antonio, USA (5-9 Dec

New Swedish study results at SABCS show DiviTum ® blood test reduces waiting times for evaluating breast cancer treatment

Uppsala, Sweden, November 14, 2017. Results from a study of 142 women with newly diagnosed metastatic breast cancer will be presented by researchers from Lund University at the world’s biggest breast cancer conference in San Antonio, USA. The study demonstrates that the DiviTum® blood-based biomarker can provide more accurate prognosis than today’s standard methods.With imaging methods used for evaluating the effect of treatment, it takes about three months to evaluate whether the given therapy is effective or not. The new study demonstrates that DiviTum® accurately can predict outcome (

Elos Medtech commits to the global orthopaedic market

Orthopaedics is a strategically important business segment for Elos Medtech and today we announce our commitment to focus on and grow this market. We will dedicate resources and develop a strong cross-site platform to further build our competence and capacity in support of our global customers. Elos Medtech announces that Jodie Gilmore, Managing Director Elos Medtech Onyx, will take up a new role as Orthopaedic Business Director and lead our global orthopaedic strategy as we continue our journey focusing entirely on the medical device industry. “Elos Medtech is excited to highlight

Hansa Medical Interim report July – September 2017

July-September in brief ›› Combined data from three independent clinical Phase II studies with Hansa Medical’s lead candidate IdeS was published in The New England Journal of Medicine 2017;377:442-53, August 3, 2017 issue. Data from these studies show that IdeS effectively reduces HLA antibodies and enables patients with very poor prognosis, who are unlikely to find a kidney donor, to be transplanted. Importantly, patients were doing well with good kidney function at last follow up. ›› Patient enrollment on target to have all patients recruited and treated by the end of 2017 in two

Hexagon Showcases Digital, Safe and Connected Solutions at Smart City Expo World Congress

Hexagon AB, a leading global provider of information technology solutions, will showcase its solutions for digital, safe and connected smart cities in Barcelona, Spain at Smart City Expo World Congress , the leading international event for smart cities.Driven by disruptive innovation, Hexagon’s information technology portfolio empowers customers with integrated data feeds and seamless workflows to create smart ecosystems, which Hexagon calls Smart X. From smart cities, smart power plants, and smart factories, to smart mines and smart farms,

OX2 sells 21.6 MW wind farm in Sweden to Fontavis

Fontavis, a Swiss asset manager within the energy and infrastructure field, has signed a purchase agreement with OX2 for six turbines at Stigshöjden with a total output of 21.6 MW.OX2 began work on the Stigshöjden wind farm, which is in Västernorrland, 35 km southwest of Örnsköldsvik, earlier this year. OX2 will also manage the park for Fontavis when the wind farm is completed in the autumn of 2019. Its expected average production is approximately 62 GWh per year. “Stigshöjden and the collaboration with OX2 is an ideal starting position to leverage Fontavis’ activities in the Nordics”

Rottneros invests another 117 SEKm within the framework of Agenda 500

As a next step in the capacity development of Rottneros Mill, Rottneros’ Board has granted further investments in the CTMP line. The investment, CTMP Step 2, increases capacity by approximately 18,000 tonnes per year and is expected to be operational in the fall of 2018. The investment follows the strategic development plan Agenda 500, where a first capacity-enhancing investment in the CTMP line was made in 2016. Within Agenda 500, Rottneros Mill has put into operation a bio mass boiler in the third quarter of 2017 that replaces an oil-based boiler and made the mill practically fossil-free.

Interim report January - September 2017

Third quarter 2017 ·Revenues amounted to SEK 180.7 (127.2) million, an increase by 42 % compared to the same period last year. ·Operating profit amounted to SEK 52.9 (54.6) million, a decrease by 3 %. ·Profit before tax amounted to SEK 52.6 (54.6) million, and profit after tax amounted to SEK 40.6 (42.3) million. ·Cash flow from operating activities amounted to SEK 70.3 (102.7) million, and cash flow from investing activities amounted to SEK -79.2 (-30.8) million. ·By the end of the period cash and short term placements amounted to SEK 244.3 (215.1)

There are no items matching the current filter
There are no more items matching the current filter
Back to top